JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 24 No. 4 316-325
© 1983 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahl, R. L.
Right arrow Articles by Philpott, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahl, R. L.
Right arrow Articles by Philpott, G. W.

Improved Radioimaging and Tumor Localization with Monoclonal F(ab')2

Richard L. Wahl, Charles W. Parker and Gordon W. Philpott

Mallinckrodt Institute of Radiology, Howard Hughes Medical Institute at Washington University School of Medicine, and the Jewish Hospital of St. Louis, St. Louis, Missouri

Correspondence: For reprints contact: Dr. Richard L. Wahl, Div. of Nucl. Med. Mallinckrodt Institute of Radiology, 510 South Kingshighway, St. Louis, MO 63110.

ABSTRACT

Monocional anti-tumor antibodies have great promise for radioimmunodetection and localization of tumors. Fab and F(ab')2 fragments, which lack the Fc fragment of antibody (Ab), are cleared more rapidly from the circulation and may have less nonspecific tissue binding than intact Ab. In radioimaging studies using a murine monocional antibody to carcinoembryonic antigen in a human colon carcinoma xenografted into hamsters, F(ab')2 fragments were shown superior to Fab fragments and intact antibody for scintiscanning. In double-label experiments with anti-CEA antibody and control monocional lgG, F(ab')2 fragments were found to give better and more rapid specific tumor localization than intact antibody or Fab fragments. F(ab')2 fragments offer significant promise for tumor imaging and possibly therapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. M. Sharkey, H. Karacay, T. M. Cardillo, C.-H. Chang, W. J. McBride, E. A. Rossi, I. D. Horak, and D. M. Goldenberg
Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Clin. Cancer Res., October 1, 2005; 11(19): 7109s - 7121s.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C.-H. Chang, R. M. Sharkey, E. A. Rossi, H. Karacay, W. McBride, H. J. Hansen, J.-F. Chatal, J. Barbet, and D. M. Goldenberg
Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies
Mol. Cancer Ther., May 1, 2002; 1(7): 553 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Kang, S. Hamilton, J. Odili, G. Wilson, and J. Kupsch
In Vivo Targeting of Malignant Melanoma by 125Iodine- and 99mTechnetium-labeled Single-chain Fv Fragments against High Molecular Weight Melanoma-associated Antigen
Clin. Cancer Res., December 1, 2000; 6(12): 4921 - 4931.
[Abstract] [Full Text]

Home page
 ScienceHome page
R. Bird, K. Hardman, J. Jacobson, S Johnson, B. Kaufman, S. Lee, T Lee, S. Pope, G. Riordan, and M Whitlow
Single-chain antigen-binding proteins
Science, October 21, 1988; 242(4877): 423 - 426.
[Abstract] [PDF]

Home page
 ScienceHome page
M Better, C. Chang, R. Robinson, and A. Horwitz
Escherichia coli secretion of an active chimeric antibody fragment
Science, May 20, 1988; 240(4855): 1041 - 1043.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1983 by the Society of Nuclear Medicine.